

Open-Angle Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

https://marketpublishers.com/r/O26D63E04302EN.html

Date: May 2022

Pages: 81

Price: US\$ 2,000.00 (Single User License)

ID: O26D63E04302EN

Abstracts

Open-Angle Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

SUMMARY

Open-Angle Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Open-Angle Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured



in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

NOTE:

This is an "on-demand" report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma.

The pipeline guide reviews pipeline therapeutics for Open-Angle Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Open-Angle Glaucoma therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Open-Angle Glaucoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.



The pipeline guide reviews latest news related to pipeline therapeutics for Open-Angle Glaucoma.

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Open-Angle Glaucoma.

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contents

Introduction

Report Coverage

Indication - Overview

Indication - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Indication - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Indication - Companies Involved in Therapeutics Development

Company 1

Company 2

Company 3

Company XX

Indication - Drug Profiles

Drug 1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug 2 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug 3 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug 4 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug XX - Drug Profile



Product Description

Mechanism of Action

R&D Progress

Indication - Dormant Projects

Indication - Discontinued Products

Indication - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development for Indication, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Indication - Pipeline by Company 1, 2022

Indication - Pipeline by Company 2, 2022

Indication - Pipeline by Company 3, 2022

Indication - Pipeline by Company XX, 2022

Indication - Dormant Projects, 2022

Indication - Discontinued Products, 2022



List Of Figures

LIST OF FIGURES

Number of Products under Development for Indication, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022



I would like to order

Product name: Open-Angle Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule

Type and Key Players

Product link: https://marketpublishers.com/r/O26D63E04302EN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/O26D63E04302EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



